CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

CVRx (NASDAQ: CVRX) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The presentation begins at 3:45 p.m. PT and will be available via live webcast at the company's investor site. An archived recording will be posted after the live event and accessible at the same URL for a limited time.

This is a company investor presentation and not an earnings release or regulatory filing.

Key Figures

Conference edition 44th Annual J.P. Morgan Healthcare Conference referenced in the announcement

Presentation date Jan. 14, 2026 Scheduled date of CVRx presentation at the conference

Presentation time 3:45 p.m. PT Start time of the J.P. Morgan conference presentation

Market Reality Check

$8.03 Last Close

Volume Volume 227,736 is about 1.44x the 20-day average of 158,001 shares. normal

Technical Shares traded below the 200-day MA, at $8.03 vs MA $8.23, before this news.

Peers on Argus 1 Up

Sector peers showed mixed moves, with examples from -4.44% to +39.91%, and only one momentum-listed peer (BWAY, up 4.97%) without news, suggesting this conference update is stock-specific rather than part of a broad sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 19	Conference participation	Neutral	-1.1%	Management fireside chat at Piper Sandler healthcare conference webcast to investors.
Nov 05	Earnings results	Positive	-2.0%	Q3 2025 revenue growth, higher gross margin, narrowed net loss and updated guidance.
Nov 04	Conference presentation	Neutral	-3.6%	Management presentation at Jefferies Global Healthcare Conference with live webcast.
Oct 22	Earnings scheduling	Neutral	+1.5%	Announcement of Q3 2025 earnings release date and accompanying conference call details.
Aug 04	Earnings results	Positive	-9.9%	Q2 2025 revenue growth, favorable CMS payment proposals, but ongoing net loss reported.

Pattern Detected

Recent CVRx news, including earnings and conference appearances, was often followed by modestly negative next-day moves, even when fundamentals like revenue growth and margins improved.

Recent Company History

This announcement continues a pattern of CVRx highlighting investor-relations events after reporting strengthening fundamentals. In Q2 2025 and Q3 2025, the company posted revenue growth with improving gross margins and reiterated or refined guidance, yet shares moved lower after those earnings. The company has also regularly participated in healthcare conferences, such as Jefferies in November 2025 and Piper Sandler in December 2025, which provided visibility but did not trigger sustained positive price reactions ahead of this J.P. Morgan appearance.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-11-06

$150,000,000 registered capacity

An effective Form S-3 shelf filed on 2025-11-06 allows CVRx to offer up to $150,000,000 of various securities over time via prospectus supplements, providing flexibility to raise capital, which can be beneficial for funding but may be dilutive when utilized.

Market Pulse Summary

The stock is down -6.5% following this news. A negative reaction despite this routine conference notice would fit prior patterns where CVRx’s positive fundamentals coincided with short-term share pressure. Past earnings in Q2 and Q3 2025 showed revenue growth and margin improvement, yet shares moved lower afterward. The company’s Form S-3 shelf for up to $150,000,000 of securities also provided flexibility for future capital raises, a factor that may have influenced risk perceptions around new corporate updates.

Key Terms

neuromodulation medical

"commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

cardiovascular diseases medical

"neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team"

Cardiovascular diseases are conditions that affect the heart and blood vessels, such as heart attacks, strokes, and chronic circulation problems. They matter to investors because how common these illnesses are, the availability of effective treatments, and regulatory or reimbursement changes directly affect demand for drugs, medical devices, and services—similar to how widespread car issues create steady business for repair shops and parts makers.

webcast technical

"A live webcast of the event can be found at ir.cvrx.com."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The Company's presentation will begin at 3:45 p.m. (PT). 

A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.

About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com 

Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com 

FAQ

When will CVRx (CVRX) present at the J.P. Morgan Healthcare Conference in 2026?

CVRx will present on Wednesday, Jan. 14, 2026 at 3:45 p.m. PT.

How can investors watch the CVRx (CVRX) presentation on Jan. 14, 2026?

Investors can watch a live webcast at the company's investor website: ir.cvrx.com.

Will the CVRx (CVRX) presentation at J.P. Morgan be available after the live event?

Yes, an archived recording will be posted after the live event and available at the same investor site for a limited time.

What topics will CVRx (CVRX) management cover at the Jan. 14, 2026 presentation?

The announcement states management will present recent company developments and outlook; no specific agenda items or financial data were provided.

Where is the 44th Annual J.P. Morgan Healthcare Conference taking place for the CVRx (CVRX) presentation?

The conference takes place in San Francisco, where CVRx management will present on stage.